|
"Tumor size, lymph node status, and use of adjuvant systemic therapy played little role. HER-2 overexpression was not associated with an increased risk in these patients (none of whom were treated with trastuzumab) (P = .91). However, epidermal growth factor receptor (EGFR) overexpression was associated with increased risk (P = .02)."
Is this not saying that HER-2 is a subset of the symptom group. So it may not be good news after all but bad news for all equally?.
AND?
Also EGFR is that not HER 1 (I must write them down or print them out as I get them mixed up), and there has been much discussion on cross talk between the HER family - so I suppose as the receptor balance shifted from HER2 to HER1 in drug resistance etc you might expect to see more cases in the HER1,2,3,4 group??.
Please check this out as it if off the top of my head as I have not had time to double check.
If somebody more knowledgeable could comment I would be grateful.
RB
|